Gilead Sciences, Inc.

Gilead Sciences, Inc.


Market Cap$87.17B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Gilead Sciences, Inc.Gilead Sciences, Inc.180.14.24%3%3.21.4

Earnings Call Q4 2023

February 6, 2024 - AI Summary

Gilead Sciences reported strong full-year and fourth quarter performance in 2023, with 7% growth in product sales (excluding Veklury) driven by HIV and Oncology.
HIV sales grew by almost $1 billion, with Biktarvy sales increasing 14% to nearly $12 billion and gaining market share in the US.
Oncology sales grew 37% to almost $3 billion, driven by Kite cell therapies and Trodelvy.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

16.6% upsideGilead Sciences Target Price DetailsTarget Price

Current Fair Value

5.5% upside

Undervalued by 5.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$87.17 Billion
Enterprise Value$106.31 Billion
Dividend Yield$2.9696 (4.24%)
Earnings per Share$0.39
Outstanding Shares1,245,853,209
Avg 30 Day Volume9,013,420


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio180.11
Price to Sales3.18
Price to Book Ratio5.0
Enterprise Value to Revenue3.87
Enterprise Value to EBIT11.99
Enterprise Value to Net Income219
Total Debt to Enterprise0.24
Debt to Equity1.44

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Gilead Sciences, Inc.

CEO: Daniel O'Day